Modality
Nanobody
MOA
DLL3 ADC
Target
PARP
Pathway
Ferroptosis
AMLDLBCLUC
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
Oct 2020
→ Dec 2030
Phase 1Current
NCT03838496
2,390 pts·UC
2020-10→2030-12·Terminated
2,390 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-284.7y awayPh2 Data· UC
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2030-12-28 · 4.7y away
UC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03838496 | Phase 1/2 | UC | Terminated | 2390 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP |